WeightWatchers’ second quarter drew a positive market response, with management citing a deliberate shift toward higher-value membership tiers and clinical offerings as key drivers of performance. The company highlighted growth in its Core+ and Med+ subscriber bases, which offset declines in its traditional core behavioral segment. Interim Chief Operations Officer Jonathan Volkmann emphasized, “Our approach combines access to effective FDA-approved GLP-1 medications with expert guidance, setting us apart in an evolving industry landscape.”
Is now the time to buy WW? Find out in our full research report (it’s free for active Edge members).
WeightWatchers (WW) Q2 CY2026 Highlights:
- Revenue: $162.3 million vs analyst estimates of $159.1 million (14.2% year-on-year decline, 2% beat)
- EPS (GAAP): $1.41 vs analyst estimates of $0.67 (significant beat)
- Adjusted EBITDA: $39.76 million vs analyst estimates of $43.82 million (24.5% margin, 9.2% miss)
- The company reconfirmed its revenue guidance for the full year of $627.5 million at the midpoint
- EBITDA guidance for the full year is $110 million at the midpoint, above analyst estimates of $107.9 million
- Operating Margin: 8.1%, down from 28.1% in the same quarter last year
- Market Capitalization: $150.1 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From WeightWatchers’s Q2 Earnings Call
There were no analyst questions on the call because the Q&A session did not occur.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will focus on (1) further progress in shifting subscribers toward higher-value Core+ and clinical tiers, (2) the sustainability of gross margins amid evolving business mix and cost structure, and (3) the effectiveness of partnerships like the Medicare GLP-1 bridge and Sam’s Club in attracting and retaining members. Execution in technology upgrades and continued debt reduction will also be closely monitored.
WeightWatchers currently trades at $14.99, down from $15.41 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
